Industry Focus Transcripts

The team opens up their mailbag to discuss goodwill and major foodservice distributors.

Here's what has changed in banking over the past 25 years, and what we think is in store for the next 25.

Digging through the company's earnings release, two Fools break down what went wrong for Fitbit last year, and what management is doing to turn things around and find growth in 2017.

Motley Fool veteran contributor Tyler Crowe calls in and gives a global view of the energy markets from his current location in Malawi.

Two analysts examine companies that benefit from the 21st Century Cures Act and also discuss top healthcare stocks to buy in 2017.

The premium cosmetics company is trading at all-time highs -- here’s what long-term investors need to know know before putting this stock on their watch list.

Big players are starting to make big moves as the energy markets gain some certainty -- here's what you need to know.

Your guide to the nitty-gritty of investing in funds.

Long-term investors could use this recent dip in the homebuilding space to buy a few of these fantastic companies.

These three small-caps are scrappy, sticky, and have a lot of room to grow -- and some incredibly solid business models that can help them do that.

Here’s a roundup of the past week’s news from Wells Fargo, Goldman Sachs, Morgan Stanley, and SunTrust.

Competitors make headway against Teva Pharmaceutical's top seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.

Apple and Snap reported very different earnings last week. Here are the most important details and what they mean.

Will Airbnb launch its IPO in 2017? Is Macau officially on track for a recovery? Will Japan eventually become the new casino capital of the world? Fool.com contributor Seth McNew shares his insights after traveling through the region.

You should definitely have some international exposure in your portfolio, but you don't need to buy foreign stocks to get it.

We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.

Ford is making some big changes to its U.S. market, but it’s not abandoning the region or sedan production altogether.

We explain why Facebook and Shopify are two tech stocks we really like and answer Gaby Lapera's questions about the companies.

Activist investors want to do a deal, but management might not be willing.

This exciting video streaming company is making a few Fools put an asterisk on their “stay away from fresh IPOs” rule.